Topic: Price Transparency
CMS wants drug companies to put their list prices in television ads, but whether that policy is something it can enforce remains a major question.
The Trump administration is planning to force drug companies to include the list price of their products in direct-to-consumer advertising.
As part of its ongoing efforts to protect the 340B program, the AHA unveiled a set of “stewardship principles” to boost transparency.
Drug rebates negotiated by pharmacy benefit managers are a popular topic for politicians. But CVS CEO Larry Merlo doesn't see either going away soon.
Axios took a deep dive into hospital pricing data from CMS, plus more healthcare headlines.
Industry groups are weighing in on CMS’ final Inpatient Prospective Payment System rule, and they see both pros and cons in the regulation.
The Maryland Health Care Commission expanded its price transparency initiative with hospital cost comparison tools for consumers.
Variability in specialty drug coverage among commercial payers raises questions about the rationale behind coverage decisions.
Health policy experts blamed hospital consolidation and a lack of price transparency as some of the key drivers of ballooning healthcare costs.
Making good on its promise, CMS unveiled its inaugural Medicaid/CHIP scorecard but dodged on whether it'll punish states that receive poor scores.